The GD2-specific chimeric antibody combined with interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF) was approved by the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) in 2015 for the treatment of HR-NB [15, 16]. The gene discussed is IL2; the disease is neuroblastoma.